Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

2results about How to "Reduce antagonism" patented technology

A fulvic acid hydrogen peptide biological stimulant fertilizer and a preparation method thereof

The application discloses a kind of fulvic acid hydrogen peptide biological stimulant hormone fertilizer and preparation method thereof, belong to fertilizer technical field.Fertilizer is by 15~30 parts of fulvic acid, 5~12 parts of peony seed meal small molecule peptide, 20~35 parts of potassium dihydrogen phosphate and other components compound, water is made up to 100 parts, and auxiliary agent is emulsifier and chelating agent compound.Preparation first by dissolving fulvic acid, potassium phosphate in water and obtaining mixed solution, then adding small molecule peptide and auxiliary agent and stirring until the system is stable;Small molecule peptide is prepared by peony seed meal defatted powder crushing and enzymolysis, solves the problem of traditional fertilizer nutrient antagonism, unstable system, and the utilization of peony seed meal also improves resource utilization.Tomato, cucumber seedling test shows that it can significantly improve the growth index of crop root system and aboveground part, and the root-promoting and seedling-strengthening effect is better than that of similar fertilizer on the market, and the preparation process is simple, easy to industrialization, and has good agricultural application prospect.
Owner:YANTAI BAOLIN GUODU FERTILIZER CO LTD

Macrorings for treatment of autoimmune diseases

PendingCN122003423Ahigh antagonistic activityStrong cytotoxicityOrganic active ingredientsSenses disorderImmunologic disordersAutoimmune condition
The present application relates to compounds of formula (I) which act as antagonists of STING, useful in the treatment of autoimmune diseases, inflammatory diseases, nervous system disorders, metabolic diseases, cardiovascular diseases, ocular diseases or selective cancer types in which overexpression or activation of STING is associated.
Owner:F HOFFMANN LA ROCHE & CO AG